China’s Good Clinical Practice (GCP) has evolved to align closely with the International Council for Harmonisation (ICH) guidelines. Emphasizing scientific credibility, ethical standards, and patient safety, China’s regulatory adjustments signify its commitment to synchronize its pharmaceutical standards with international best practices, ensuring consistency in global drug development and approvals.